|
|
Article: MammaPrint(R) Breast Cancer Test Provides Valuable Insight for Personalized Treatment Decisions.
- Article from:
- PR Newswire
- Article date:
- May 30, 2008
CopyrightCOPYRIGHT 2008 PR Newswire Association LLC. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
Results presented at major U.S. cancer conference
CHICAGO, May 30 /PRNewswire/ -- Agendia BV, a world leader in the rapidly evolving field of molecular diagnostics, announced today that data from two studies involving its MammaPrint(R) breast cancer prognosis test will be presented at the American Society of Clinical Oncology's (ASCO) annual meeting. Collectively, these findings show that MammaPrint, a prognostic test for breast cancer recurrence using a 70-gene signature, provides important information for more effective patient management.
"These studies demonstrate the clinical utility of MammaPrint in helping physicians make more informed decisions ...